Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Two Imiquimod Cream 5%

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have 4 to 8 clinically diagnosed, non-hyperkeratotic, non-hypertrophic AK lesions within a 25 cm2 contiguous treatment area on either the face or balding scalp~* Women either must be 1 year post-menopausal, surgically sterile, or agree to use a medically accepted form or birth control~* Free of any systemic or dermatological disorder~* Any skin type or race, providing the skin pigmentation will allow discernment of erythema~Exclusion Criteria:~* Basal cell or squamous cell carcinoma, or other possible confounding skin conditions (on face and scalp)~* History of cutaneous hyperreactivity or facial irritation to topical products~* Engaging in activities involving excessive or prolonged exposure to sunlight~* Receiving systemic cancer chemotherapy, psoralen plus UVA therapy, UVB therapy, laser abrasion, dermabrasion, glycolic acids, or chemical peels 6 months prior to study entry~* Currently using or have used systemic steroids 2 months prior to study~* Currently using or have used on the treatment area over-the-counter retinol products, corticosteroids, cryosurgery, curettage, 5-fluorouracil, or other topical actinic keratosis treatments 28 days prior to randomization~* Pregnant or nursing mothers~* History of allergy or sensitivity to imiquimod or related compounds or other components of the formulation~* Taking immunosuppressant medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imiquimod 5% Taro (Type: EXPERIMENTAL): Imiquimod 5% manufactured by Taro applied for 16 weeks
- Aldara - Imiquimod 5% (Type: ACTIVE_COMPARATOR): Aldara, Imiquimod 5% applied for 16 weeks
- Vehicle (Type: PLACEBO_COMPARATOR): Imiquimod vehicle applied for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).